… metastatic castration-sensitive prostate cancer with homologous recombination … altered metastatic castration-resistant prostate cancer (mCRPC). Adding … prostate cancer and homologous recombination repair mutations. The combination showed statistically …

… survival (OS) did not reach statistical significance (HR, 0.78; … patients with metastatic castration-sensitive prostate cancer receiving Nubeqa (darolutamide) plus … darolutamide for metastatic castration-sensitive prostate cancer. OncLive®. June 3, 2025. …

… ) led to a statistically significant improvement in disease … to high-risk localized prostate cancer, according to data … - to high-risk prostate cancer.” According to Candel … freedom from biochemical failure, prostate cancer-specific outcomes, and overall …

… ;caac.21834. Accessed June 2025. Prostate Cancer: Statistics. Cancer.Net. https:/… .net/cancer-types/prostate-cancer/statistics. Accessed June 2025. American …

… patients with metastatic castration-sensitive prostate cancer (mCSPC), according to a … analysis, there was no statistically significant improvement to overall survival … patients with metastatic hormone-sensitive prostate cancer. News release. Bayer. November …

… treatment of metastatic castration-sensitive prostate cancer (mCSPC). The approval is supported … ) Congress. The study demonstrated a statistically significant improvement in rPFS for … study did not show a statistically significant improvement in OS with …

… men with castration-resistant prostate cancer (CRPC), regardless … resulting in a statistically significant improvement in … metastatic castration-resistant prostate cancer with bone metastases,” … men with castration-resistant prostate cancer (CRPC) with bone …

… treatment of metastatic castration-sensitive prostate cancer, according to a news … placebo arm. There was no statistically significant difference in overall survival … patients with metastatic castration-sensitive prostate cancer. All patients also received a …

… tolerability profile of darolutamide for prostate cancer patients across all approved indications … eventually progress to castration-resistant prostate cancer (CRPC), a condition with … F et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence …

… patients with metastatic castration-sensitive prostate cancer (mCSPC) with alterations in homologous … rPFS are supported by a statistically significant benefit in time to … (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with …